JP2023503031A5 - - Google Patents
Info
- Publication number
- JP2023503031A5 JP2023503031A5 JP2022528949A JP2022528949A JP2023503031A5 JP 2023503031 A5 JP2023503031 A5 JP 2023503031A5 JP 2022528949 A JP2022528949 A JP 2022528949A JP 2022528949 A JP2022528949 A JP 2022528949A JP 2023503031 A5 JP2023503031 A5 JP 2023503031A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- chain variable
- variable region
- pharmaceutical combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/120021 | 2019-11-21 | ||
| CN2019120021 | 2019-11-21 | ||
| PCT/CN2020/129964 WO2021098748A1 (en) | 2019-11-21 | 2020-11-19 | Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503031A JP2023503031A (ja) | 2023-01-26 |
| JP2023503031A5 true JP2023503031A5 (https=) | 2023-11-28 |
Family
ID=75979930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528949A Pending JP2023503031A (ja) | 2019-11-21 | 2020-11-19 | 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230002499A1 (https=) |
| EP (1) | EP4061844A4 (https=) |
| JP (1) | JP2023503031A (https=) |
| CN (3) | CN114729048A (https=) |
| WO (3) | WO2021098750A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023746A2 (pt) | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| SG10201708048XA (en) * | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CA2942245C (en) * | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| SG11201607969XA (en) * | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| KR20160146747A (ko) * | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| AU2015264102C1 (en) * | 2014-05-23 | 2020-10-08 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| US20160152720A1 (en) * | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| SG10201807625PA (en) * | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| MA41218A (fr) * | 2014-12-19 | 2017-10-24 | Advaxis Inc | Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr |
| WO2016145030A1 (en) * | 2015-03-11 | 2016-09-15 | Providence Health & Services-Oregon | Compositions and methods for enhancing the efficacy of cancer therapy |
| DK3303396T5 (da) * | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| JP2018521019A (ja) * | 2015-06-08 | 2018-08-02 | ジェネンテック， インコーポレイテッド | 抗ｏｘ４０抗体を使用して癌を治療する方法 |
| ES2994611T3 (en) * | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| US11633506B2 (en) * | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| CN108623685B (zh) * | 2017-03-25 | 2022-07-01 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| JP2021501801A (ja) * | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
-
2020
- 2020-11-19 JP JP2022528949A patent/JP2023503031A/ja active Pending
- 2020-11-19 WO PCT/CN2020/129966 patent/WO2021098750A1/en not_active Ceased
- 2020-11-19 CN CN202080080402.0A patent/CN114729048A/zh active Pending
- 2020-11-19 CN CN202080081256.3A patent/CN114729051A/zh active Pending
- 2020-11-19 US US17/778,512 patent/US20230002499A1/en not_active Abandoned
- 2020-11-19 WO PCT/CN2020/129965 patent/WO2021098749A1/en not_active Ceased
- 2020-11-19 EP EP20889168.9A patent/EP4061844A4/en not_active Withdrawn
- 2020-11-19 CN CN202080080393.5A patent/CN114729047A/zh active Pending
- 2020-11-19 WO PCT/CN2020/129964 patent/WO2021098748A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037894A5 (https=) | ||
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2019519499A5 (https=) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| RU2006132466A (ru) | Высококонцентрированные жидкие композиции анти-egfr антител | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN109963592A (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2018534933A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| JP2010535713A5 (https=) | ||
| RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| JP2009102444A5 (ja) | 二次性骨腫瘍の治療のための抗PDGFRα抗体 | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| JP2022516351A5 (https=) | ||
| JP2023518153A5 (https=) |